ANGPT2 and neoplasm: Moreover, TME regulation focusing on the tumor endothelial cells with new molecules targeting the Ang-2 pathway and DII4 inhibitors have demonstrated anti-tumor activity in sunitinib and sorafenib resistant RCCs [62,63,153].